5-year, long-term safety from CLL/SLL studies1

In pooled data from multiple open-label rollover and follow-up studies in both treatment-naïve and relapsed/refractory CLL/SLL patients (N=808), the median treatment duration was 51 months (range 0.2 to 98 months). Due to types of events collected and less frequent clinic visits, limited data were collected from one follow-up study.

Discontinuations Due to AEs2*

*3 subjects discontinued ibrutinib with primary reason for discontinuation due to adverse event. However, there is no corresponding TEAE leading to study drug discontinuation for those three subjects at time of study drug discontinuation.